Clinical trials for Plasma cell tumor
50 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGN/ANCT07446777FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor DiseaseUniversity of Miami · PI: Tracy E Crane, PhD, RDN
- RECRUITINGPhase 1NCT07333261Study of BMS-986453 in Newly Diagnosed Multiple MyelomaSusan Bal · PI: Susan Bal, MD
- RECRUITINGPhase 3NCT07258511A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaJanssen Research & Development, LLC
- RECRUITINGPhase 1NCT07093554Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple MyelomaMedical College of Wisconsin · PI: Othman Akhtar, MBBS
- RECRUITINGPhase 2NCT06920251Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab TherapySeoul National University Hospital
- RECRUITINGPhase 2NCT06822972HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMMDuke University · PI: Yubin Kang, MD
- RECRUITINGN/ANCT07045727Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Older Patients Undergoing CAR-T Therapy for Relapsed or Refractory Multiple MyelomaMayo Clinic · PI: Nadine H. Abdallah, MD
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT07210047Study of HuL001 in Relapsed/Refractory Multiple Myeloma PatientsHuniLife Biotechnology, Inc. · PI: Maisie Huang, PhD
- RECRUITINGPhase 2NCT07106736MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple MyelomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1, PHASE2NCT07099391A Study of Dara-RVd and Teclistamab-RVd in People With Multiple MyelomaMemorial Sloan Kettering Cancer Center · PI: Neha Korde, MD
- ACTIVE NOT RECRUITINGN/ANCT06924424Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple MyelomaPeking University People's Hospital
- RECRUITINGPhase 2NCT06793449BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple MyelomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPhase 2NCT06668792An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple MyelomaBiocad
- RECRUITINGPhase 3NCT06679101A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)GlaxoSmithKline
- RECRUITINGPhase 1NCT06433947Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple MyelomaOpna Bio LLC
- RECRUITINGPhase 1NCT06225310A Trial of Selinexor, Ruxolitinib and MethylprednisoloneOncotherapeutics · PI: James Berenson, MD
- RECRUITINGPhase 1NCT06574568A Study of YKST02 in Participants With Relapsed or Refractory Multiple MyelomaExcyte Biopharma Ltd · PI: Wenming Chen, MD
- RECRUITINGPhase 3NCT06187441FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)Stichting Hemato-Oncologie voor Volwassenen Nederland · PI: Sonja Zweegman, Prof Dr MD
- RECRUITINGPhase 1NCT06271252A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL StudyOriCell Therapeutics Co., Ltd.
- RECRUITINGPhase 3NCT05764044Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical CancerHospital do Coracao
- RECRUITINGPhase 1NCT05546723LMY-920 for Treatment of Relapsed or Refractory MyelomaLuminary Therapeutics · PI: Leland Metheny, MD
- RECRUITINGPHASE1, PHASE2NCT06105554Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple MyelomaM.D. Anderson Cancer Center · PI: Robert Orlowski, M D
- RECRUITINGPhase 3NCT06208150A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideJanssen Research & Development, LLC · PI: Janssen Research & Development, LLC Clinical Trial
- ACTIVE NOT RECRUITINGPhase 1NCT05981209Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted TherapiesAbdullah Khan · PI: Abdullah M Khan, MBBS, MSc
- RECRUITINGPhase 3NCT05730036A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple MyelomaRegeneron Pharmaceuticals · PI: Clinical Trial Management
- ACTIVE NOT RECRUITINGN/ANCT05853887Liquid Biopsy Based NGS in Newly Diagnosed NSCLCCharu Aggarwal · PI: Charu Aggarwal, MD, MPH
- ACTIVE NOT RECRUITINGEarly Phase 1NCT05560399A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple MyelomaIcahn School of Medicine at Mount Sinai · PI: Samir Parekh, MBBS
- ACTIVE NOT RECRUITINGN/ANCT05587972Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom MonitoringCarevive Systems, Inc. · PI: Aaron Galaznik, MD
- RECRUITINGPhase 3NCT05519085A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)Celgene · PI: Bristol-Myers Squibb
- ACTIVE NOT RECRUITINGPhase 3NCT04975997Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)Celgene · PI: Bristol-Myers Squibb
- RECRUITINGPhase 1NCT05055063A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple MyelomaM.D. Anderson Cancer Center · PI: Robert Orlowski
- ACTIVE NOT RECRUITINGNCT06366802Cohort Construction and Prognostic Model Construction for Multiple MyelomaThe First Affiliated Hospital of Soochow University
- RECRUITINGPhase 1NCT04795882A New Study Evaluating the Activity of Modular CAR T for mYelomaUniversity College, London
- ACTIVE NOT RECRUITINGPhase 2NCT05177536Iberdomide Maintenance Therapy in Patients With Multiple MyelomaUniversity of Nebraska · PI: Sarah A Holstein, MD, PhD
- RECRUITINGPhase 2NCT05145400Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple MyelomaUNC Lineberger Comprehensive Cancer Center · PI: Sascha Tuchman, MD
- ACTIVE NOT RECRUITINGPhase 1NCT04684108SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological MalignanciesHangzhou Sumgen Biotech Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT04973605A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaBeOne Medicines
- ACTIVE NOT RECRUITINGPhase 2NCT04653246Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMMJacob Laubach, MD · PI: Jacob C Laubach, MD
- RECRUITINGPhase 1NCT04483206Personalized Autologous Transplant for Multiple MyelomaEmory University · PI: Craig C Hofmeister, MD
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04808037Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaHellenic Society of Hematology · PI: Meletios-Athanasios Dimopoulos
- ACTIVE NOT RECRUITINGPhase 1NCT04613557Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple MyelomaCelyad Oncology SA
- ENROLLING BY INVITATIONNCT05775224ASH Research Collaborative Data HubASH Research Collaborative
- ACTIVE NOT RECRUITINGPhase 1NCT04091126Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple MyelomaGlaxoSmithKline · PI: GSK Clinical Trials
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT07217119Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMMGlaxoSmithKline
- ACTIVE NOT RECRUITINGPhase 2NCT03589222SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple MyelomaPETHEMA Foundation
- RECRUITINGNCT07260370The Difference of microRNA and Circulating Tumor Cells in Blood Among Cancer Patients With ImmunotherapyChang Gung Memorial Hospital · PI: Chia-Hsun Hsieh, PhD
- ACTIVE NOT RECRUITINGN/ANCT02911571PRospective Multiple Myeloma Impact StudySkylineDx · PI: Saad Usmani, MD
- ACTIVE NOT RECRUITINGPhase 1NCT03070327BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple MyelomaMemorial Sloan Kettering Cancer Center · PI: Sham Mailankody, MD
- ACTIVE NOT RECRUITINGPhase 2NCT02538198Lenalidomide Maintenance in Plasma Cell MyelomaMemorial Sloan Kettering Cancer Center · PI: Alexander Lesokhin, MD
- ACTIVE NOT RECRUITINGPhase 2NCT02420860Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaM.D. Anderson Cancer Center · PI: Sheeba Thomas